INTRODUCTION
Mycobacterium tuberculosis accounts for the largest number of deaths caused by a single human pathogen with predictions of an excess of 80 million new cases and 20 million deaths in the coming decade. The appearance of drug-resistant strains of M. tuberculosis and the HIV pandemic have exacerbated this situation. Effective treatment of tuberculosis infections requires the identification of new drugs, drug targets and drug-resistance factors. The ATP-binding cassette (ABC) transporters [1] constitute a large superfamily of multi-subunit permeases that transport diverse molecules (ions, amino acids, peptides, drugs, antibiotics, lipids, polysaccharides, proteins etc.) at the expense of ATP [2, 3] . The genes encoding the ABC transporters occupy about 2.5 % of the genome of M. tuberculosis [4] . At least 37 complete and incomplete ABC transporters have been identified in M. tuberculosis based on the structural similarities of the typical subunits of ABC transporters present in all living organisms. Knowledge of these M. tuberculosis ABC transporters is necessary both for understanding their involvement in the development of multidrug resistance in M. tuberculosis as well as in the export of the unique antigenic cell-surface components of this organism, such as the phthiocerol mycocerosates and lipoarabinomannan.
The prototype eukaryotic ABC transporter is P-glycoprotein [5] . The 170 kDa P-glycoprotein is characterized by two membrane integral domains with six membrane-spanning helices each connected with two ATP-hydrolysing domains and the presence of ' Walker sites A and B ' [6] in the primary structure of the ATPhydrolysing domains, which, by analogy with ATP-and GTPAbbreviations used : ABC, ATP-binding cassette ; BCECF-AM, 2h,7h-bis-(2-carboxyethyl)-5(6)-carboxyfluorescein acetomethoxyl ester ; DIM, phthiocerol dimycocerosate ; IPTG, isopropyl β-D-thiogalactoside ; MIC, minimum inhibitory concentration. 1 To whom correspondence should be addressed (e-mail parul!bosemain.boseinst.ac.in).
of the two polypeptides was essential to obtain a functional doxorubicin efflux pump. Expression of DrrAB in E. coli conferred 8-fold increased resistance to ethidium bromide, a cationic compound. 2h,7h-bis-(2-Carboxyethyl)-5(6)-carboxyfluorescein (BCECF), a neutral compound, also behaved as a substrate of the reconstituted efflux pump. When expressed in M. smegmatis, DrrAB conferred resistance to a number of clinically relevant, structurally unrelated antibiotics. The resistant phenotype could be reversed by verapamil and reserpine, two potent inhibitors of ABC transporters.
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binding proteins, bind nucleotides [7, 8] . The doxorubicinresistance operon, first identified in Streptomyces peucetius [9] , shares similarity with the eukaryotic P-glycoprotein. Two translationally coupled open reading frames, drrA and drrB, encode an ABC-type transporter, with drrA encoding the nucleotidebinding domain and drrB encoding the membrane integral component [10] . A monomer of DrrA and DrrB forms a molecule about half the size of P-glycoprotein. The likely stoichiometry of the functional transporter is DrrA # B # [10] . By analogy to S. peucetius, the completed M. tuberculosis genome [11] also contains a doxorubicin-resistance operon, drr. In addition, the drr operon has been identified in the genomes of Mycobacterium leprae and Mycobacterium a ium. As powerful techniques of molecular biology have become available, the drr operon has assumed particular significance in relation to its implications in the virulence of M. tuberculosis. The biosynthesis of phthiocerol dimycocerosates (DIMs) involves several genes [12] . The genes pps A-E encode a type I modular polyketide synthase responsible for the synthesis of phthiocerol and phenolphthiocerol. Another gene, mas, encodes an iterative type I polyketide synthase that produces mycocerosic acid. The gene fadD28 is probably involved in the release and transfer of mycocerosic acid from Mas on to the diols. These seven genes are clustered on a 50 kb fragment of the chromosome containing, among other genes, the open reading frames of the drr operon and mmpl7, encoding polypeptides similar to ABC transporters. Signature-tagged transposon mutagenesis has shown that transposon insertions in the drr operon or mmpl7 lead to a strong growth defect of M. tuberculosis in the lungs of intravenously infected mice [13, 14] and in export of DIM to the cell surface [15] .
The biochemical characterization of the Drr transporter assumes obvious importance in the light of these recent observations. Its association with virulence suggests that it presents an attractive drug target, which if inactivated will probably disable the pathogen in terms of its ability to export complex molecules such as DIM, a surface-exposed antigenic lipid present in seven pathogenic species of mycobacteria [16] , to the cell surface. In addition, the likely importance of the drr operon in multidrug resistance deserves evaluation. The biochemical characterization of the drr operon was undertaken before most of these recent observations came to light, envisaging its likely importance in multidrug resistance of M. tuberculosis. The goal was to develop expression systems expressing a functional DrrAB transporter in order to evaluate the role of the transporter in drug resistance as well as to exploit the expression systems in further characterization of the transporter in relation to the roles of the conserved domains in transport function. 
EXPERIMENTAL

Strains
Cloning was performed in Escherichia coli DH5α. E. coli LMG194 (Invitrogen) and E. coli BL21(DE3) (Novagen) were used for protein expression. Mycobacterium smegmatis mc#155 has been described by Snapper et al. [17] .
Amplification and cloning of drrAB from cosmid MTCY19H9
The drrAB operon was amplified from the cosmid MTCY19H9 (a kind gift from Stewart Cole, Institut Pasteur, Paris, France) using the primer pair 5h-CGGGGTACCATATGCGCAACGA-CGACATGGC-3h (sense) and 5h-CCCGAATTCGTCGTGAT-CATGGGCCGCCTAG-3h (antisense) with asymmetric KpnI and EcoRI sites (underlined) in the sense and antisense primers respectively. The PCR product was digested with KpnI and EcoRI, cloned into the vector pUC19 between the KpnI and EcoRI sites to generate the plasmid pCKB101, and sequenced on both strands. The sequenced drrAB gene was excised from pUC19 and cloned between the NdeI (indicated above in bold) and EcoRI sites of the expression vector pET 28a + (Novagen) to give the plasmid pCKB102.
Cloning of the drrA and drrB genes
The drrA gene was amplified from plasmid pCKB101 using the following primer pair : 5h-CGGGGTACCATATGCGCAACG-ACGACATGGC-3h (sense) and 5h-ATAGAATTCATCGCGC-GGACCCCGACACCAG-3h (antisense) with asymmetric KpnI and EcoRI sites, and cloned into the vector pK18 [18] between the KpnI and EcoRI sites (underlined) to generate the plasmid pCKB104. pCKB104 was sequenced and the drrA gene was excised and cloned between the NdeI (shown above in bold) and EcoRI sites of pET28a + to give pCKB105.
The drrB gene was amplified from plasmid pCKB101 using the following primer pair : 5h-GAAGATCTCATATGAGCGGCC-CG-3h (sense) and 5h-CCCGAATTCGTCGTGATCATGGGC-CGCCTAG-3h (antisense) with asymmetric BglII and EcoRI sites, cloned in the vector pK18 to give pCKB107 and sequenced. The drrB gene was excised and cloned between the NdeI and EcoRI sites of pET28a + to give pCKB108, as well as between the BglII and EcoRI sites of pBAD-HisA to give pCKB109.
Construction of an artificial operon
pCKB108 was digested with NcoI and NdeI to eliminate a 58 bp fragment. This was replaced by oligonucleotide 5h-CATGGCT-GGTACCGGGGTCAAGGAGATAACA-3h and its reverse complement strand, with overhangs of CATG at the 5h-end and AT at the 3h end to complement NcoI and NdeI respectively. The resulting plasmid, termed pCKB110, contained a KpnI site (underlined) and a Shine-Dalgarno sequence (AGGA).
The drrA gene was amplified from pCKB105 using the primers 5h-GAAGATCTCA T A T GCGCAACGACGACATGGC-3h (sense) and 5h-GGAATTCGGTACCAGATGGGTCAGAGA-CTCGGT-3h (antisense) with asymmetric NdeI and EcoRI sites and cloned between the NdeI and EcoRI sites of pET28a + to give pCKB111. Plasmid pCKB110 was digested with KpnI and EcoRI and the fragment containing the drrB gene with the upstream Shine-Dalgarno sequence was cloned between the KpnI (shown above in bold) and EcoRI sites of pCKB111 to give pCKB112. pCKB112 therefore contains the translationally coupled drrAB genes, with the artificial ribosome-binding site AGGA upstream of the drrB gene, under the control of the T7 promoter.
The following cloning steps were performed to introduce the Myc epitope at the C-terminal end of DrrB. Using pCKB112 as a template, the drrA and drrB genes were amplified using the primer pair 5h-GAAGATCTCATATGCGCAACGACGACA-TGGC-3h (sense ; primer DrrA-His) and 5h-AAAAAGCTTTG-GCCGCCTAGCCAAAACGTTTTGGCTAGGCGGCCA-3h (antisense ; BglII and HindIII sites in the sense and antisense primers are underlined) and cloned between the BglII and HindIII sites of pBAD myc HisA to give plasmid pCKB113 carrying a translational fusion of the Myc epitope to the C-terminal end of DrrB. Primer DrrA-His was used as the sense primer paired with the antisense primer 5h-ATGGAATTCTCAGTCGACGGCGC-TATTCAGATC-3h (EcoRI site underlined) for amplification using pCKB113 as the template, and the product was cloned between the BamHI and EcoRI sites of pET28a + to give pCKB114. pCKB114 carried the drrA gene fused to an upstream sequence encoding a hexahistidine tag, and the drrB gene fused to a downstream sequence encoding a Myc epitope. Further cloning was performed to place the His-drrA-drrB-myc-encoding sequence under the control of the mycobacterial Hsp60 promoter in a shuttle vector with E. coli and mycobacterial origins of replication (derived from pYUB12) [17] and a kanamycinresistance marker, generating the plasmid pCKB115.
Expression of proteins in E. coli
Recombinant plasmids derived from pET28a + were transformed in E. coli BL21(DE3). Cells were grown to mid-logarithmic phase (D '!! l 0.6) in Luria broth and induction was carried out at different temperatures with different concentrations of isopropyl β--thiogalactoside (IPTG). Recombinant plasmids derived from pBad-HisA were transformed into E. coli LMG194 cells (Invitrogen pBAD manual) and induced with varying concentrations of arabinose at different temperatures.
Expression of proteins in M. smegmatis mc 2 155
Electroporation of M. smegmatis mc#155 with the plasmid pCKB115 was performed as described by Larsen [19] . Transformants were grown in Luria broth supplemented with 25 µg\ml kanamycin up to a D '!! value of 0.8, followed by heat shock.
Fractionation of cells and localization of proteins
After induction E. coli cells were suspended in 10 mM Tris\HCl (pH 7.4), 1 mM MgCl # , 1 mM PMSF, 20 µg\ml leupeptin, 10 µg\ml pepstatin and 10 µg\ml aprotinin, and sonicated thrice at 200 W for 15 s. The unbroken cells were removed by centrifugation at 500 g for 5 min. Inclusion bodies were obtained by centrifugation at 5000 g for 5 min. Membranes were obtained by centrifugation at 100 000 g for 60 min, and the supernatant constituted the cytosolic extract. Membranes from M. smegmatis transformants were prepared as described by Basu et al. [20] .
ATP-binding experiment
Photolabelling of membranes was carried out with [α-$#P]ATP (Easytides ; NEN) at varying concentrations and a specific activity of 0.25 mCi\mmol in 10 mM Tris\HCl, pH 7.4, containing 10 mM dithiothreitol. Where indicated, doxorubicin was added to the reaction mixture to a final concentration of 50 or 100 µM and MgCl # was added to a final concentration of 5 mM. The reaction was carried out in a volume of 25 µl in a 96-well microtitre plate kept on a block of ice directly under UV illumination (254 nm) for 30 min. Samples were analysed by SDS\PAGE and autoradiography.
Minimum inhibitory concentrations (MICs)
E. coli BL21(DE3)\pCKB114 or M. smegmatis\pCKB115 were induced as described above to express DrrA and DrrB. MICs were determined by the broth microdilution method according to National Committee for Clinical Laboratory Standards guidelines [21] . Cells were added at 10' colony-forming units\ml in microtitre wells (in duplicate) containing serial dilutions of different drugs. Controls without drug were also run. The plate was incubated at 37 mC overnight (for E. coli) or 48 h (for M. smegmatis). MIC was defined as the lowest concentration of drug with complete absence of growth (A '!! 0.05, i.e. a value equal to visible growth). Each MIC was determined at least thrice using three different transformants.
Uptake of [ 14 C]doxorubicin
Cells expressing DrrA and DrrB were grown up to midlogarithmic phase, induced, harvested and suspended to a D '!! value of 20 in 50 mM potassium phosphate, pH 7.4, containing 5 mM MgSO % . Uptake was initiated (in the absence or presence of inhibitors) by the addition of doxorubicin (5 µM ; 10-50 µCi\mmol). Cells were diluted into ice-cold 10 mM potassium phosphate, pH 7.4, containing 0.1 M LiCl, filtered on glass fibre (Whatman GF\C) filters, dried and counted in a liquid scintillation counter.
Uptake of BCECF-AM
This was done as described by Bolhuis et al. [22] . The cells were harvested and washed thrice with 50 mM Hepes buffer, pH 7.3, containing 25 mM K # SO % and 5 mM MgSO % . Subsequently, the cells were resuspended in the buffer to a final D '!! value of 20. BCECF-AM (2 mM stock solution in DMSO) was added to the cell suspension to a final concentration of 1 µM. BCECF fluorescence was monitored continuously at excitation and emission wavelengths of 502 and 525 nm respectively, in a Hitachi F-4500 spectrofluorimeter, equipped with a thermostatically controlled (37 mC), magnetically stirred cuvette holder.
RESULTS
Expression and localization of DrrA in E. coli
DrrA was expressed in E. coli BL21(DE3)\pCKB105 at 30 mC at an IPTG concentration of 100 µM for 4 h ( Figure 1A) . The protein localized primarily in the inclusion bodies (results not shown).
Expression of DrrB in E. coli
Attempts to express DrrB (cloned in the vector pE28a + ) in E. coli BL21(DE3) were abortive. The expressed protein appeared to be extremely sensitive to proteolysis. DrrB was also cloned in the vector pBAD-HisA (Invitrogen) under the control of the araBAD promoter and expressed in E. coli LMG-194. This was done in view of the fact that the araBAD promoter (pBAD) of E. coli allows regulated expression, facilitating optimum expression of protein in its properly folded form. Briefly, transformed cells were grown up to a D '!! of 0.6 in RM-glucose medium with 50 µg\ml ampicillin as described in the Invitrogen pBAD manual. Cells were induced with 0.002 % arabinose at 30 mC for 4 h. Induced cells were pelleted down, subjected to three cycles of freezing and thawing, and run on SDS\polyacrylamide (12.5 %) gels. Expressed DrrB migrated as a polypeptide of apparent molecular mass 31 kDa ( Figure 1B) . DrrB localized exclusively to the membranes. However, it still remained sensitive to proteolytic degradation. Attempts to extract it from membranes using various detergents were abortive.
Tandem expression of DrrA and DrrB
When E. coli BL21(DE3)\pCKB102 harbouring the drrAB genes was induced with 50 µM IPTG, the expression of DrrA was visible on polyacrylamide gels, but the expression of DrrB could not be visualized. An artificial operon was therefore constructed to allow the simultaneous expression of DrrA and DrrB. An artificial ribosome-binding site was introduced upstream of the drrB gene ( Figure 1D) , and the drr A and drrB genes were fused downstream of a hexahistidine-encoding sequence and upstream of a Myc-epitope-encoding sequence, respectively, in the vector pET28a + to give the plasmid pCKB114. Induction of DrrA and DrrB was found to be optimal when carried out using 50 µM IPTG at 30 mC for 4 h. Membranes, cytosolic extracts and inclusion bodies were prepared as described above. In crude cell extracts, bands corresponding to both DrrA and DrrB were visible on SDS\polyacrylamide gels. Both DrrA and DrrB were present exclusively in the membranes of these cells (Figure 1C, lanes 1 and 2) , as confirmed by Western blotting with anti-His and anti-Myc antibodies ( Figure 1C, lanes 3 and 4) . E. coli transformants could be stored as glycerol stocks at k70 mC for several weeks without loss of expression of DrrAB.
Expression of DrrAB in M. smegmatis
In order to evaluate the functional characteristics of the DrrAB efflux pump in mycobacteria, conditions were optimized for expression of both DrrA and DrrB under the control of the heat- shock promoter Hsp60 in M. smegmatis. Heat shock was given at temperatures ranging from 37 to 45 mC for varying periods of time (30 min to 2 h). Optimum expression was observed following heat shock at 42 mC for 45 min. Both components of the pump localized to the membranes of induced cells as judged by Western blotting using anti-His and anti-Myc antibodies ( Figure 1E ). M. smegmatis transformants could be stored as glycerol stocks at k70 mC for 2 weeks, after which transformants showed very slow growth when cultured in liquid medium.
[α-32 P]ATP binding
UV-catalysed binding of [α-$#P]ATP to DrrA was observed when E. coli membranes expressing DrrA and DrrB were used sim-
Figure 3 [ 14 C]Doxorubicin accumulation in E. coli (A) and M. smegmatis (B) expressing DrrA and DrrB
Steady-state accumulation levels of doxorubicin in uninduced (solid bars) cells were taken to be 100 %. Accumulation in uninduced and induced (hatched bars) cells in the absence of inhibitors was termed controls. Where indicated, induced cells were incubated with 5 µM doxorubicin and increasing concentrations ( µg/ml) of reserpine. Data expressed represent the meanspS.D. of three separate determinations using three different batches of transformants.
ultaneously for binding studies (Figure 2) . The binding was enhanced in the presence of both doxorubicin and daunorubicin ( Figure 2 ). It is possible that both these drugs induce a conformational change in DrrA, favouring interaction with ATP.
Uptake of [ 14 C]doxorubicin
["%C]Doxorubicin uptake was studied in E. coli cells harbouring plasmid pCKB114 designed for tandem expression of DrrA and DrrB. Doxorubicin was used at a concentration of 5 µM (which did not affect cell viability). Doxorubicin uptake was significantly lower in cells induced to express DrrAB compared with uninduced cells, suggesting that the tandemly expressed DrrA and DrrB proteins were associating to form a functional doxorubicin efflux pump ( Figure 3A) . This was further confirmed by determining doxorubicin accumulation after addition of reserpine (at sublethal concentrations), an inhibitor of ATP-dependent efflux pumps. On addition of reserpine, doxorubicin accumulation in cells expressing both DrrA and DrrB increased to levels similar to that observed in uninduced cells. DrrAB therefore appeared to associate to form a functional doxorubicin efflux pump. Accumulation levels in cells expressing DrrA or DrrB alone were similar to uninduced cells (results not shown). The uptake of doxorubicin in M. smegmatis was again found to be inhibitable by reserpine ( Figure 3B ), suggesting that the pump is functional in M. smegmatis. In E. coli and in M. smegmatis, the difference in accumulation in the induced and uninduced states while being statistically significant ranged between 2.5 and 3-fold.
BCECF-AM transport
BCECF-AM is a non-fluorescent, neutral compound which diffuses across the cytoplasmic membrane. Once inside the cell, BCECF-AM is rapidly hydrolysed by non-specific esterases, trapping the non-permeant hydrophilic free acid BCECF within the cell. BCECF accumulated after the addition of BCECF-AM to E. coli BL21(DE3)\pET28a + or to E. coli BL21(DE3)\ pCKB114. Intracellular accumulation was strongly reduced in the latter case compared with cells containing vector alone. The expression of DrrAB therefore appeared to play a role in decreased accumulation of BCECF, suggesting that neutral compounds may also serve as substrates of the Drr pump. 
Effect of DrrAB expression on drug susceptibility
E. coli BL21(DE3)\pCKB114 expressing DrrA and DrrB simultaneously showed increased resistance to ethidium bromide, doxorubicin, daunorubicin, chloramphenicol and puromycin (Table 1 ). Cells expressing DrrA or DrrB alone behaved like cells harbouring the vector pET28a + or the vector pBAD-HisA alone (results not shown). The DrrAB pump is likely involved in the transport of DIM to the cell surface in M. tuberculosis. In addition, another physio- logical role of such a pump could be to pump out toxic lipophilic metabolites or hydrophobic compounds which are encountered in the extracellular environment. To address the role of DrrAB in antibiotic resistance in mycobacteria, the MICs of M. smegmatis expressing DrrAB towards a range of clinically relevant antibiotics were determined. DrrAB conferred resistance to a broad range of clinically relevant antibiotics, including tetracycline, erythromycin, ethambutol, norfloxacin, streptomycin and chloramphenicol. This suggested a possible role that it might play in antibiotic resistance of M tuberculosis. The differences in the fold enhancement of MICs (in the case of some drugs) due to the expression of DrrAB observed between E. coli and M. smegmatis may be attributed to (a) different roles of the permeability barrier, (b) roles of other efflux pumps, (c) differences in target sensitivities and (d) different druginactivating mechanisms in the two organisms.
DISCUSSION
The principal physiological role of the Drr proteins of M. tuberculosis appears to be in the export of complex lipids to the cell exterior. The role of ABC transporters in lipid transport is now being acknowledged widely [23] . The role of the drr operon in transport of DIM to the cell surface in M. tuberculosis has also been documented [15] . The results of drug susceptibility profiling in the E. coli and M. smegmatis expression systems for DrrAB developed by us suggest a role of this pump in resistance against hydrophobic drugs. The attempts to express the two proteins individually in E. coli suggest that neither of the two proteins retains its integrity in the absence of the other protein. DrrB appeared to be exquisitely sensitive to proteolysis in the absence of DrrA. The use of the artificial operon to achieve simultaneous expression of DrrA and DrrB allows the demonstration of the interdependence of the two proteins. The targeting of DrrA to the membranes is facilitated by the co-expression of DrrB, while the stability of DrrB in the membranes is facilitated by the simultaneous presence of DrrA in the membranes.
In E. coli, both cationic hydrophobic compounds such as doxorubicin and neutral compounds such as BCECF appeared to be substrates of the functional DrrAB efflux pump. The expression of the pump in E. coli imparted 8-fold increased resistance to ethidium bromide, a cationic substrate of ABC transporters. Increased adduct formation with [α-$#P]ATP in the presence of doxorubicin or daunorubicin raised the possibility that substrate binding to the pump induces a conformational alteration favouring ATP binding to DrrA. This is similar to the observation that doxorubicin stimulates ATP binding to DrrA of S. peucetius [24] . Whether it does so by binding to a site in the DrrA protein or exerts an indirect effect after binding to DrrB is open to question. Drug-stimulated ATPase activity has been reported in the case of the human P-glycoprotein [25] . The overexpression of a functional doxorubicin efflux pump from M. tuberculosis and its inhibition by known inhibitors of ABC transporters, such as reserpine, exemplifies the characterization of an ABC transporter for the first time from this globally important pathogen, and demonstrates that it imparts resistance to hydrophobic drugs. The use of doxorubicin accumulation to determine functionality of the DrrAB pump provides an assay system for biochemical characterization of this pump. The difference in accumulation levels between induced and uninduced cells ranges between 2.5-and 3-fold in E. coli and M. smegmatis. This suggests that only inhibitors that inhibit the pump almost completely are likely to be picked up without ambiguity using this assay system. Similarly, the effects of mutations of conserved amino acid residues are likely to be reflected unambiguously when such mutations inhibit the pump almost completely. Nevertheless, the expression systems described here deserve further evaluation considering that development of an assay system based on the likely natural substrate DIM appears even more technically challenging and elusive.
The differences in MIC observed in M. smegmatis expressing DrrAB suggest that this pump confers resistance towards a broad range of structurally unrelated drugs in mycobacteria. This is like the observation that LmrA, the Lactococcus lactis counterpart of the human P-glycoprotein, shows broad substrate specificity [26] . The M. smegmatis assay system is likely to be useful in evaluating drugs of potential against mycobacteria by virtue of their ability to inhibit DrrAB. On the other hand, the E. coli expression system is more robust ; with E. coli transformants being more stable than M. smegmatis transformants when stored as glycerol stocks at k70 mC. E. coli also has the advantage of a faster generation time than M. smegmatis.
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